Hayley Virgil

No overlapping toxicities and a tolerable safety profile were seen with the addition of talquetamab to daratumumab in a population of patients with relapsed/refractory multiple myeloma.

Research shows that tamoxifen treatment may lead to problems down the road in patients with primary breast cancer.

While the benefit is yet to be determined in those with favorable-risk disease, patients with advanced renal cell carcinoma experienced improvements in both progression-free and overall survival after being treated with first-line immunotherapy vs sunitinib.

Rapid responses and tolerable safety was shown with minimal residual disease–based consolidation therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

Th of plasma cell-free methylomes offers investigators a method to monitor tumor responses to treatment noninvasively, according to findings presented during the AACR Annual Meeting 2021.

Adjuvant trastuzumab is showing promising long-term results in patients with HER2-positive early breast cancer, a population that is representative of most patients seen in clinical practice.

Updated findings from the early-stage KRYSTAL-1 study showed that treatment with adagrasib resulted in durable responses, broad disease control, and provided extensive predicted coverage throughout the dosing interval in patients with KRAS G12Cmutant advanced non–small cell lung cancer.

A combination of zandelisib and zanubrutinib induced significant responses, including several complete responses in patients with relapsed or refractory chronic lymphocytic leukemia and other B-cell lymphomas in a phase 1b study, the results of which were presented during the 2021 European Hematology Association Annual Congress.

Results from the phase 2 LTHAIC study showed that adding toripalimab and hepatic arterial infusion chemotherapy to lenvatinib achieved robust and durable responses in patients with advanced hepatocellular carcinoma.

Results from the final analysis of the phase 1b FORWARD II trail, show that mirvetuximab soravtansine combined with bevacizumab yielded durable responses in patients with recurrent, platinum agnostic ovarian cancer, a population with an unmet need for more effective, non-platinum treatments.

New results, presented at the 2021 ASCO annual meeting, show the benefit of adding durvalumab to neoadjuvant anthracycline and taxane–based chemotherapy for patients with early triple-negative breast cancer.

Promising responses rates were seen with larotrectinib, a highly selective, central nervous system-active TRK inhibitor, in patients with TRK fusion cancer, including in those with CNS metastases at baseline.

Early results of a phase 2 study show that the efficacy achieved with the combination of ponatinib and blinatumomab represents a potentially promising chemotherapy-free, hematopoietic stem cell transplant–sparing treatment for patients with Philadelphia chromosome–positive acute lymphocytic leukemia.

Findings from the phase 3 REACH2 trial demonstrated a lower risk of relapse and longer median duration of response with ruxolitinib versus best available therapy in patients with steroid-refractory acute graft-versus-host disease.

PFS Doubles for Advanced Melanoma Patients Treated with Relatlimab Plus Nivolumab.

Data from patients with relapsed/refractory diffuse large B-cell lymphoma treated with axicabtagene ciloleucel showed that post-chimeric antigen receptor T outcomes may not correlate with responsiveness observed with treatment received immediately prior.

In patients with non-muscle invasive bladder cancer carcinoma in-situ who were unresponsive to Bacillus Calmette-Guerin, the addition of N-803 induced a high rate of complete responses, findings from a cohort of the phase 2/3 QUILT-3.032 study showed.

Patient-reported outcomes from the phase 3 ADAURA trial showed that adjuvant osimertinib maintained health-related quality of life compared with placebo in patients with EGFR-positive non–small cell lung cancer.

Patients with EGFR-mutant, MET-amplified or -overexpressed non–small cell lung cancer and MET resistance treated with osimertinib in combination with savolitinib may be able to overcome resistance, according to final analysis findings.

Step counts appeared to correlate with self-reported quality of life during the first 2 weeks of treatment with SM-88 in patients with metastatic pancreatic cancer, the results of a preliminary exploratory analysis from part 2 of the phase 2/3 TYME-88-Panc trial showed.

Although the use of TMB as a biomarker has been established in certain tumors, such as non–small cell lung cancer, the pan-cancer approval came as a surprise to some in the oncology community.

Patients with HER2-positive metastatic breast cancer and brain metastases treated with the combination of tucatinib, trastuzumab, and capecitabine had significantly lengthened the time to deterioration of health-related quality of life, according to the results of an analysis of the HER2CLIMB clinical trial presented during the 2020 San Antonio Breast Cancer Symposium.

Pathologic complete responses were improved when neoadjuvant atezolizumab was added to nab-paclitaxel followed by doxorubicin plus cyclophosphamide compared with placebo in combination with chemotherapy as treatment of patients with early triple-negative breast cancer without adding additional treatment burden to patients.

Patients with Oncotype Dx low-risk recurrence scores were classifed with high accuracy by PreciseDx by using only hematoxylin and eosin stain images and limited clinical data.

MEDI2228 demonstrated promising clinical efficacy as treatment of patients with relapsed/refractory multiple myeloma with triple-refractory disease experiencing maintained responses in a phase 1 study.

In a pooled analysis of 4 clinical trials in chronic lymphocytic leukemia, patients who received treated with acalabrutinib monotherapy had a low incidence of cardiac toxicities leading to treatment discontinuation, according to a presentation given during the American Society of Hematology Annual Meeting.

Adult patients with acute lymphoblastic leukemia who have relapsed following hematopoietic cell transplantation have experienced considerably improved survival benefits over the past few years, which may be due to an increased use of immunotherapy.

The most important factor associated with poor survival among patients below 60 years of age with acute myeloid leukemia was self-reported black race in a SEER analysis.

Patients with relapsed or refractory multiple myeloma had deep and durable responses to the BCMA- and CD3-targeted bispecific monoclonal antibody REGN5458, early on in the course of treatment, according to findings from a first-in-human phase 1 study.

Treatment with a novel tri-specific natural killer cell engager agent led to natural killer cell proliferation across dose levels in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia.